Back    Zoom +    Zoom -
UNITED LAB, Novo Nordisk Sign Exclusive Licensing Agreement for UBT251
Recommend
15
Positive
14
Negative
5
UNITED LAB (03933.HK) announced that it had entered into an exclusive licensing agreement with its wholly-owned subsidiary United Biotechnology and Novo Nordisk for UBT251, a triple agonist of the receptors of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes and other diseases.


AAStocks Financial News
  • Remark
  • (1) HK Indices are real time
Home|RT Quote|Market|News|Indices
Feedback|Disclaimer
View: Mobile|Desktop
Lang: 繁|简|EN
Back To Top
Contact Us
Email: support@aastocks.com